Glucotrack Director Departs, CEO Appointed to Board
Ticker: GCTK · Form: 8-K · Filed: Jan 29, 2025 · CIK: 1506983
Sentiment: neutral
Topics: director-departure, new-director, executive-compensation, employment-agreement
TL;DR
Glucotrack director out, CEO Ben-Haim joins board and gets new employment deal.
AI Summary
Glucotrack, Inc. announced on January 27, 2025, the departure of Director David J. Glickman. The company also elected Dr. Shlomo Ben-Haim as a new director and appointed him to the Compensation Committee. Additionally, the company entered into a new employment agreement with its Chief Executive Officer, Dr. Shlomo Ben-Haim, effective January 27, 2025.
Why It Matters
Changes in board composition and executive employment agreements can signal shifts in company strategy or leadership focus.
Risk Assessment
Risk Level: medium — Changes in directorship and executive compensation can indicate internal shifts that may impact future performance.
Key Players & Entities
- Glucotrack, Inc. (company) — Registrant
- David J. Glickman (person) — Departing Director
- Dr. Shlomo Ben-Haim (person) — Newly Elected Director and CEO
- January 27, 2025 (date) — Effective date of changes
FAQ
Who has departed from the Glucotrack, Inc. board of directors?
David J. Glickman has departed from the board of directors of Glucotrack, Inc.
Who has been elected as a new director to Glucotrack, Inc.'s board?
Dr. Shlomo Ben-Haim has been elected as a new director to Glucotrack, Inc.'s board.
What committee has Dr. Shlomo Ben-Haim been appointed to?
Dr. Shlomo Ben-Haim has been appointed to the Compensation Committee.
What is the effective date of the new employment agreement for the CEO?
The new employment agreement for the CEO, Dr. Shlomo Ben-Haim, is effective January 27, 2025.
What other item information is reported in this 8-K filing?
This 8-K filing also reports on Regulation FD Disclosure and Financial Statements and Exhibits.
Filing Stats: 1,242 words · 5 min read · ~4 pages · Grade level 10.8 · Accepted 2025-01-29 09:28:36
Key Financial Figures
- $300,000 — Agreement provides for a base salary of $300,000 per annum for 2025, and for fiscal year
- $450,000 — r 2026 and thereafter, a base salary of $450,000 per annum (the "Base Salary"). Mr. Wulf
- $75,000 — lestones. These include: (i) a bonus of $75,000 upon the successful closing of one or m
- $6 m — ng of one or more transactions totaling $6 million, (ii) an additional $125,000 upon
- $125,000 — totaling $6 million, (ii) an additional $125,000 upon the closing of one or more transac
- $12 m — transactions with a cumulative value of $12 million, and (iii) an additional $62,500
- $62,500 — of $12 million, and (iii) an additional $62,500 upon the closing of one or more transac
- $18 m — transactions with a cumulative value of $18 million, each payable at the end of the m
Filing Documents
- form8-k.htm (8-K) — 50KB
- ex10-1.htm (EX-10.1) — 67KB
- ex99-1.htm (EX-99.1) — 15KB
- ex99-1_001.jpg (GRAPHIC) — 3KB
- 0001493152-25-004104.txt ( ) — 328KB
- gctk-20250127.xsd (EX-101.SCH) — 3KB
- gctk-20250127_lab.xml (EX-101.LAB) — 33KB
- gctk-20250127_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: January 29, 2025 GLUCOTRACK, INC. By: /s/ Paul Goode Name: Paul Goode Title: Chief Executive Officer